TRENDING :  Market Movers  |  Top 50   SPY (0.09%)    CGC (8.29%)    CASY (-1.42%)    BABA (-0.84%)    BA (-1.29%)    ATVI (0.07%)    ARCW (-0.88%)    APC (-0.19%)    SPG (-2.45%)    SCIF (-2.32%)    RYAAY (-2.36%)    PANW (1.63%)    PAGS (1.51%)    MU (0%)    MMYT (-0.2%)    MJ (3.05%)    MHK (-0.29%)    MBRX (168.47%)    M (-3%)    INTC (0.57%)    GOOGL (0.99%)    GDXJ (-2.07%)    FRT (-1.98%)    FIS (1.2%)    EWZ (0.08%)

 ALKS - Alkermes plc

$33.67 [0.1][0.27%]

Next Earnings

4/25/2019

BMO

Recommend
Trade Idea »



OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $ALKS

TRENDING ARTICLES



Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

04/18/19
The market expects Alkermes ALKS to deliver a year over year decline in earnings on lower revenues when i t report s results for the quarter ended March 2019 This widely known consensus outlook is important in assessing the company s earnings picture but a powerful factor that might

Alkermes Reports Positive Data From Schizophrenia Study

04/10/19
Alkermes plc ALKS announced positive top line results from ALPINE Aripiprazole 160 Lauroxil and 160 Paliperidone palmitate 160 INitiation 160 Effectiveness a six month phase IIIb study evaluating the efficacy safety and tolerability of its long acting

Analysts Predict 10% Gains Ahead For VUG

03/28/19
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the

Recro Pharma Falls as FDA Denies Approval to Pain Candidate

03/26/19
Shares of Recro Pharma Inc REPH plunged 34 on Mar 25 following a complete response letter CRL to the new drug application NDA seeking approval of its pain candidate meloxicam The company was looking to get this approval to the intravenous IV administration of meloxicam for